10106419A precision medicine approach for treating psychotic disordersClosedCollaborative R&DInnovate UKDisorders such as schizophrenia affect 1.5% of the population across the world and are lifelong, disabling illnesses. Whilst schizophrenia affects a smaller proportion of the global population than for example, depression, the global burden of disease is estimated to be the highest among the mental health disorders and with annual costs greater than those for all cancers combined. One of the symptoms of schizophrenia for which there is no available treatment is problems with cognition (e.g. memory, concentration). One of the reasons it is difficult to treat is that the cause of the cognitive symptoms are varied and so not all patients will respond to one treatment. Monument has developed a test (known as a biomarker) to identify patients with cognitive symptoms which will respond to a specific drug treatment we are developing (MT1988). This project is for the work of formulating and manufacturing the first batch of a new treatment in development for cognitive impairment in schizophrenia, MT1988\. Monument has the opportunity to work with a large non-profit organization on a clinical study which will administer MT1988 to a group of patients at high risk of developing schizophrenia. This project comprises the preparatory work for the clinical trial to allow Monument to participate in the collaboration and includes 1) formulation and manufacture of MT1988 and 2) protection of newly generated IP for process development of MT1988\.